What 4 Analyst Ratings Have To Say About Nurix Therapeutics
Portfolio Pulse from Benzinga Insights
Nurix Therapeutics (NASDAQ:NRIX) has received 4 analyst ratings in the last quarter, with 2 being bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target for the company is $25.25, a decrease of 21.09% from the previous average of $32.00.
September 07, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Nurix Therapeutics has received mixed analyst ratings, which could lead to uncertainty in the market.
The mixed analyst ratings indicate differing opinions about the company's future performance. This could lead to uncertainty among investors, potentially impacting the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100